Skip to main content

Lineage Cell Therapeutics, Inc.

corporate_fare Company Profile

Lineage Cell Therapeutics, Inc.

LCTX·NYSE·Life Sciences·CIK 0000876343

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Its approach, which it calls "Replace and Restore," is grounded in evidence that replacing or supporting cells that have become dysfunctional or lost can restore or replenish normal function and improve treatment and recovery. The company believes cellular therapies aimed at entirely replacing dysfunctional or destroyed cells may have more durable, broader, or more suitable applicability than traditional pharmaceutical products, which often seek to affect just a single molecular target or group of biological pathways. Lineage develops a portfolio of assets based on this mechanism. Its most clinically-advanced program is OpRegen (RG6501), an allogeneic retinal pigmented epithelial (RPE) cell replacement therapy in Phase 2a development under a worldwide collaboration with F. Hoffman-La Roche Ltd. and Genentech, Inc., a member of the Roche Group, for the treatment of geographic atrophy (GA) secondary to dry-AMD. The cells Lineage has or may seek to manufacture are intended to replace the same type of cells the patient has lost or which have become dysfunctional due to conditions such as dry age-related macular degeneration (dry-AMD), spinal cord injury (SCI), hearing loss and Type 1 Diabetes (T1D). The company views the term cell transplant as more applicable to its approach than "stem cell therapy" because it never administers stem cells to patients; instead, it uses stem cells solely as a source material from which to create and deliver partly or fully differentiated and functionally active replacement cells intended to be substantially identical to the cells affected by disease or trauma.

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for LCTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for LCTX spans 4, 8-K.

Recent high-impact activity:

  • Broadwood's Bradsher Buys 1M LCTX Shares for $770,700 Open-Market
  • Lineage Closes NeuroAirmid Buy, Adding Clinical-Stage Huntington's Program HUNT1

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$14.56M
Net Income
-$63.53M
Diluted EPS
-$0.28
Op. Cash Flow
-$18.92M
Free Cash Flow
-$19.44M
Operating Income
-$36.62M
Cash & Equivalents
$40.79M
Debt / Equity
0.00×
Net Margin
-436.5%
Shares Outstanding
243.12M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-093992

Short Interest & Short Volume

19.27 days to cover

FINRA reported short interest of 24,348,055 shares in LCTX as of the October 30, 2026 settlement, a 6.1% decrease from the prior period — about 19.3 days to cover at its recent average daily volume. On November 20, 2026, 42.7% of LCTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)24,348,055 shares as of October 30, 2026
Change vs prior period▼ 6.1%
Days to cover19.27 at avg daily volume of 1,263,570
Daily short volume (FINRA facilities)42.7% of 1,060,966 shares on November 20, 2026
5-day average short volume42.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$0.8262 +7.03% today
52-week range · as of 2026-11-19 $0.7697 – $1.99
Market cap
$195.26M
Volume
2M (1.0× avg)
3-mo avg 2M
Live data · 2026-11-21 20:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LCTX - Latest Insights

LCTX
Nov 19, 2026, 5:58 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $0.8533
Real-time Price: $0.8262 info
Change: -$0.0271 (-3%) info
Market Cap: $195.256M info
LCTX
Nov 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.8262 info
Change: -$0.1638 (-17%) info
Market Cap: $195.256M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets